Lantern Pharma Inc Equity-NMS: LTRN

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$4.48

52W high :

$7.92

1Y :

-36.08%

5Y :

-70.37%

Shares O/S :

10.86 M

Market cap :

49.02 M

What is the share price of Lantern Pharma Inc today?

Lantern Pharma Inc (LTRN) share price as of March 26, 2023, is $4.515. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Lantern Pharma Inc?

Yes, Indian Investors can invest in the Lantern Pharma Inc (LTRN) Share by opening an international trading account with Angel One.

How can I purchase Lantern Pharma Inc shares in India?

Purchasing Lantern Pharma Inc (LTRN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Lantern Pharma Inc (LTRN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Lantern Pharma Inc?

Yes, you can purchase fractional shares of Lantern Pharma Inc (LTRN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Lantern Pharma Inc?

The market capitalization of Lantern Pharma Inc on March 26, 2023, is $49.02 M.

In which sector Lantern Pharma Inc belongs?

Lantern Pharma Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Lantern Pharma Inc stocks?

In order to invest in Lantern Pharma Inc (LTRN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Lantern Pharma Inc. is a clinical stage biopharmaceutical company focused on using artificial intelligence (AI), machine learning and genomic data to streamline the drug development process. The Company's therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. Its products include LP-100, LP-300, LP-184, and LP-284, and an Antibody Drug Conjugate (ADC) program. LP-100 is in Phase II clinical trial in metastatic, castration-resistant and prostate cancer. LP-300 is focused on targeting phase II trial, in never smoking patients with NSCLC in combination with chemotherapy. LP-184 is a synthetic small molecule drug with nanomolar potency. LP-284, the stereoisomer (enantiomer) of LP-184, has shown in-vitro anticancer activity in hematological cancers. ADC Program based on the recognition of antibody drug conjugates as a therapeutic approach for cancer treatment.